Skip to main content
SGMOQ logo

SGMOQ · Sangamo Therapeutics, Inc

Track SGMOQ — free
$0.11 +0.00 (+0.00%) At close · Nov 18
Market Cap
$45.57M
Shares
414.29M
Volume · Nov 18 211.89K Avg daily vol (3M) 1.65M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.11 Open$0.11 Day$0.10–0.11 52W close$0.04–0.57 Avg vol 30d1.2M Short int8.3M · 2.0% of shares · 4.9d Short vol6% Last earningsMay 14, 2026 DataJan 2020–Nov 2026 Filing10-Q · May 14

Latest documents

2026
Oct 27
Current report 8-K Events of Oct 23
Regulation FD disclosure

Sangamo Therapeutics, Inc. filed amended July and August monthly operating reports and a September report for its bankruptcy case; its common stock was delisted effective October 17, 2026.

Read from the first part of this long document
Oct 16
Current report 8-K Events of Oct 14
Regulation FD disclosure

Sangamo Therapeutics filed its monthly operating report for August 2026 in its Chapter 11 case. It reported a net loss of -14,449,029 (cumulative -29,369,386), cash receipts of 10,145,433, disbursements of 3,826,691, and an ending cash balance of 23,225,696.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$34.56M
Trailing 12 months
Net income (TTM)
−$123.33M
Trailing 12 months
Revenue growth YoY
-77.6%
Year over year
Operating margin
-357.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-198.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$27.59M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+76.9%
Year over year · more shares
Price change (1Y)
-73.2%
Trailing year
Short interest
2.0%
Latest settlement · 4.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −42%
below
Price vs 50-day avg −15%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 13%
near low
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +5%
trailing
6-month return −50%
trailing
YTD return −74%
this year
Relative strength −47%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-71% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.02% of shares out · ▼ -2.1% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 47
elevated · 0–100
Fundamentals
Strong
Revenue growth +89%
Y/Y
EPS growth +10%
Y/Y
Free cash flow $-97.3M
Balance sheet $20.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 161%
annualized · 1-yr
Max drawdown −93%
past year
ATR 16.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 14, 2026
Total operating expenses · 2026 Lowered $110M – $130M
Mar 30, 2026 $120M – $140M changed to May 14, 2026 $110M – $130M
Non-GAAP total operating expenses · 2026 Lowered $100M – $120M
Mar 30, 2026 $110M – $120M changed to May 14, 2026 $100M – $120M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−42% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
13% Bearish
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-71% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.02% of shares out · ▼ -2.1% MoM · 4.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 13% Range high $1
vs 200-day avg -42% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SGMOQ
Sangamo Therapeutics, Inc
this stock
$45.57M -73.8% +88.6% — 2.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.0%
Net QoQ
-531.9K sh
Top holder
HANTZ FINANCIAL SERVICES,…
Held Float
View
Held by Funds
Fund positions
12
View
Short & Settlement
Short Interest Falling
Shares short
8.3M
Days to cover
4.9d
Change
-175.4K sh
View
Short Volume
Short vol %
6%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
80.0K
Value
$9.6K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
99.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$39.6M
Net income (FY)
$-122.9M
EPS diluted
$-0.44
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
21

Sangamo Therapeutics, Inc. filed amended July and August monthly operating reports and a September report for its bankruptcy case; its common stock was delisted effective October 17, 2026.

View
Proposed Sales
Value
$17.7K
Shares
69.8K
Filed
Apr 22, 2026
View
Earnings & Events
Webcasts
Last webcast
May 14, 2026
View
Investor Relations
Latest news
Sangamo Therapeutics Launches Auc…
Published
Oct 13, 2026
View

Performance

5D 20D 120D MTD YTD
SGMOQ +3.8% +4.8% -50.0% -5.2% -73.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +7.7% +10.3% -46.5% -1.8% -80.9%
Key facts CIK 1001233 CUSIP 800677106 13F (30d) 21 filings 4 filers Visit website Investor relations